Product Information
LAMIVUDINE 300 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $1.3483 per EA under NDC 33342000207. Its NADAC has been published 273 times since Feb 12, 2020.
Strength
300 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342000207
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA090198On Market Since
5/2/2019
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE 300 MG TABLET has been published 273 times since Feb 12, 2020, and over the history we have for it it has risen 22.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3483 per EA |
|---|---|
| All-time high | $2.3691 (Jun 16, 2021) |
| All-time low | $1.1052 (Feb 12, 2020) |
| 52-week high | $1.5066 |
| 52-week low | $1.2525 |
| Median price | $1.3311 |
| Average price | $1.4653 |
| Largest weekly change | +54.2% (Feb 17, 2021) |
| Weeks tracked | 273 |
| Tracking since | Feb 12, 2020 |
Generic Alternatives
The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of LAMIVUDINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 300 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $1.3483 per EA (NDC 33342000207), effective Jun 24, 2026.
How has the price of LAMIVUDINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE 300 MG TABLET has risen 22.0%. It has been tracked across 273 weekly CMS publications since Feb 12, 2020.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE 300 MG TABLET?
Since Feb 12, 2020, the NADAC for LAMIVUDINE 300 MG TABLET has ranged from a low of $1.1052 (Feb 12, 2020) to a high of $2.3691 (Jun 16, 2021), with a median of $1.3311 per EA.
Are there cheaper alternatives to LAMIVUDINE 300 MG TABLET?
Yes. 3 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LAMIVUDINE 300 MG TABLET, is $1.3014 per EA — about 3% below LAMIVUDINE 300 MG TABLET.
Who manufactures LAMIVUDINE 300 MG TABLET?
LAMIVUDINE 300 MG TABLET (NDC 33342000207) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.
Related Drugs
Same classification